Investing.com - Bio-Rad Labs (NYSE: BIO) reported first quarter EPS of $2.29, $0.14 better than the analyst estimate of $2.15. Revenue for the quarter came in at $610.8M versus the consensus estimate of $619.09M.
Bio-Rad Labs's stock price closed at $279.76. It is down -13.98% in the last 3 months and down -26.07% in the last 12 months.
Bio-Rad Labs saw 0 positive EPS revisions and 4 negative EPS revisions in the last 90 days. See Bio-Rad Labs's stock price’s past reactions to earnings here.
According to InvestingPro, Bio-Rad Labs's Financial Health score is "good performance".
Check out Bio-Rad Labs's recent earnings performance, and Bio-Rad Labs's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar